Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers.

Gopal P, Sarihan EI, Chie EK, Kuzmishin G, Doken S, Pennell NA, Raymond DP, Murthy SC, Ahmad U, Raja S, Almeida F, Sethi S, Gildea TR, Peacock CD, Adams DJ, Abazeed ME.

Nat Commun. 2019 Nov 13;10(1):5143. doi: 10.1038/s41467-019-13161-x.

PMID:
31723142
2.

Modeling cellular response in large-scale radiogenomic databases to advance precision radiotherapy.

Manem VS, Lambie M, Smith I, Smirnov P, Kofia V, Freeman M, Koritzinsky M, Abazeed ME, Haibe-Kains B, Bratman SV.

Cancer Res. 2019 Sep 26. pii: canres.0179.2019. doi: 10.1158/0008-5472.CAN-19-0179. [Epub ahead of print]

PMID:
31558563
3.

An image-based deep learning framework for individualizing radiotherapy dose.

Lou B, Doken S, Zhuang T, Wingerter D, Gidwani M, Mistry N, Ladic L, Kamen A, Abazeed ME.

Lancet Digit Health. 2019 Jul;1(3):e136-e147. doi: 10.1016/S2589-7500(19)30058-5. Epub 2019 Jun 27.

4.

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.

Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME.

Cancer Res. 2019 Nov 1;79(21):5640-5651. doi: 10.1158/0008-5472.CAN-19-0859. Epub 2019 Aug 6.

PMID:
31387923
5.

The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists.

Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.

Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):698-712. doi: 10.1016/j.ijrobp.2019.07.026. Epub 2019 Aug 2. Review.

PMID:
31381960
6.

The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics.

Balyimez A, Stephans KL, Abazeed ME, Mian OY.

J Thorac Dis. 2019 Jun;11(6):2188-2191. doi: 10.21037/jtd.2019.06.07. No abstract available.

7.

Distinct clinical and biological implications of CUX1 in myeloid neoplasms.

Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP.

Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.

8.

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME.

BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2.

9.

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP.

Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

10.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16.

11.

Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response.

Vargas R, Gopal P, Kuzmishin GB, DeBernardo R, Koyfman SA, Jha BK, Mian OY, Scott J, Adams DJ, Peacock CD, Abazeed ME.

NPJ Precis Oncol. 2018 Jul 11;2:14. doi: 10.1038/s41698-018-0060-3. eCollection 2018.

12.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
13.

The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin.

Mian OY, Tendulkar RD, Abazeed ME.

Transl Cancer Res. 2017 Dec;6(Suppl 9):S1441-S1445. doi: 10.21037/tcr.2017.10.49. No abstract available.

14.

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.

Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG.

Sci Rep. 2017 Apr 27;7(1):1232. doi: 10.1038/s41598-017-00791-8.

15.

The Vps13p-Cdc31p complex is directly required for TGN late endosome transport and TGN homotypic fusion.

De M, Oleskie AN, Ayyash M, Dutta S, Mancour L, Abazeed ME, Brace EJ, Skiniotis G, Fuller RS.

J Cell Biol. 2017 Feb;216(2):425-439. doi: 10.1083/jcb.201606078. Epub 2017 Jan 25.

16.

Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.

Velcheti V, Khunger M, Abazeed ME.

J Thorac Oncol. 2017 Feb;12(2):e16-e18. doi: 10.1016/j.jtho.2016.11.273. No abstract available.

17.

A Histologic Basis for the Efficacy of SBRT to the lung.

Woody NM, Stephans KL, Andrews M, Zhuang T, Gopal P, Xia P, Farver CF, Raymond DP, Peacock CD, Cicenia J, Reddy CA, Videtic GM, Abazeed ME.

J Thorac Oncol. 2017 Mar;12(3):510-519. doi: 10.1016/j.jtho.2016.11.002. Epub 2016 Dec 22.

18.

A genetic basis for the variation in the vulnerability of cancer to DNA damage.

Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, Rogacki K, Pearson BE, Phillips J, Raymond DP, Pennell NA, Almeida F, Cheah JH, Clemons PA, Shamji A, Peacock CD, Schreiber SL, Hammerman PS, Abazeed ME.

Nat Commun. 2016 Apr 25;7:11428. doi: 10.1038/ncomms11428.

19.

Characterizing genomic alterations in cancer by complementary functional associations.

Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, Ghandi M, Greulich H, Vazquez F, Weir BA, Van Allen EM, Tsherniak A, Shao DD, Zack TI, Noble M, Getz G, Beroukhim R, Garraway LA, Ardakani M, Romualdi C, Sales G, Barbie DA, Boehm JS, Hahn WC, Mesirov JP, Tamayo P.

Nat Biotechnol. 2016 May;34(5):539-46. doi: 10.1038/nbt.3527. Epub 2016 Apr 18.

20.

Radiotherapy in the Era of Precision Medicine.

Yard B, Chie EK, Adams DJ, Peacock C, Abazeed ME.

Semin Radiat Oncol. 2015 Oct;25(4):227-36. doi: 10.1016/j.semradonc.2015.05.003. Epub 2015 May 14. Review.

PMID:
26384271
21.

Integrative radiogenomic profiling of squamous cell lung cancer.

Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, Giacomelli AO, Du C, Fries DF, Wong KK, Mesirov JP, Loeffler JS, Schreiber SL, Hammerman PS, Meyerson M.

Cancer Res. 2013 Oct 15;73(20):6289-98. doi: 10.1158/0008-5472.CAN-13-1616. Epub 2013 Aug 26.

22.
24.

Rabies prophylaxis for pregnant women.

Abazeed ME, Cinti S.

Emerg Infect Dis. 2007 Dec;13(12):1966-7. doi: 10.3201/eid1312.070157. No abstract available.

25.
26.

Cell-free reconstitution of transport from the trans-golgi network to the late endosome/prevacuolar compartment.

Blanchette JM, Abazeed ME, Fuller RS.

J Biol Chem. 2004 Nov 19;279(47):48767-73. Epub 2004 Sep 13.

27.

Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.

Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, Yamaoka S, Seto M, Nunez G.

J Biol Chem. 2001 Jun 1;276(22):19012-9. Epub 2001 Mar 21.

Supplemental Content

Loading ...
Support Center